AMBOSS Secures €240M Funding Round
AMBOSS has successfully completed a significant financing round amounting to €240 million, attracting long-term investors committed to enhancing its innovative platform for medical education and clinical decision-making. This funding will support AMBOSS’s expansion into new international markets, further enriching its offerings to not just physicians, but also to nurses and other healthcare professionals.
Partnership with New Investors
The financing round attracted prestigious attention from notable investors including KIRKBI, M&G Investments, and Lightrock, alongside existing shareholders. This transition to a European stock corporation (SE) marks a new chapter for AMBOSS, emphasizing its commitment to long-term growth and flexibility in investment strategies.
Benedikt Hochkirchen, Co-Founder and Co-CEO of AMBOSS, expressed confidence in their investor choices: "We choose investors who are committed to our long-term vision and very flexible in the investment duration. Many of our new investors manage evergreen funds and plan to accompany us until a possible IPO and beyond." Discussions around selective acquisitions suggest AMBOSS continues to aim for strategic growth while reinforcing technological advancements.
Technological Advancements and Market Expansion
This substantial investment will facilitate AMBOSS's ongoing technological enhancements and strategic market entries. The company has already made strides in the nursing sector by acquiring Novaheal, a promising startup, and NEJM Knowledge+, a valuable resource for residents preparing for board exams in the United States.
AMBOSS's overarching goal is to digitalize healthcare by ensuring that physicians are equipped with the necessary tools and information to make informed decisions. With a user-centered design, AMBOSS integrates the latest medical insights, empowering doctors through reliable resources. Dr. Madjid Salimi, Co-Founder and Co-CEO, remarked, "Technology will not replace healthcare professionals, but those who embrace it will lead the way.”
Global Reach and Trust
More than a million healthcare professionals in over 180 countries utilize AMBOSS for medical guidance. In Germany, an impressive statistic reveals that one in every two inpatient treatments is conducted by a physician who relies on AMBOSS resources. In the United States, AMBOSS supports the educational journeys of medical students, enabling them to successfully prepare for exams while achieving higher scores compared to traditional study methods.
A remarkable 25% of first-year residents in the US count on AMBOSS to enhance their patient care skills. AMBOSS's approach combines the expertise of experienced medical professionals with advanced AI technology, providing clear recommendations tailored to the latest clinical guidelines.
The Role of AI in Clinical Practice
A crucial element of AMBOSS's success is the collaboration between medical experts and technology specialists, ensuring the platform offers precise and actionable insights. This digital co-pilot adapts to physicians' needs, streamlining their workflow and minimizing the potential for errors during patient care.
With a strong emphasis on responsible AI development, AMBOSS focuses on outcomes validation, reinforcing its commitment to providing an invaluable resource for both educators and clinicians. As the platform continues to evolve, so too does its reputation for reliability and trustworthiness in the medical community.
A Bright Future for Healthcare Professionals
Peter Bason, Head of Private Capital at KIRKBI, acknowledged the remarkable growth journey of AMBOSS, praising its innovative spirit and the unique platform that supports learning and clinical decision-making. He stated, "We are excited to partner with other experienced technology and growth investors to back AMBOSS' visionary leadership team in their mission of empowering the next generation of healthcare professionals worldwide."
About AMBOSS
Established in 2012 by a dedicated team of physicians, AMBOSS has fundamentally transformed the landscape of medical knowledge acquisition and application at the point of care. With a keen focus on top-notch content quality, innovative AI integration, and a user-centered philosophy, the company has grown to encompass over 500 employees from more than 50 countries, including over 150 physicians and numerous tech experts. More than 1 million medical professionals globally depend on AMBOSS's resources. This commitment to excellence continues to position AMBOSS as a key player in modern healthcare education.
Frequently Asked Questions
What is the significance of AMBOSS's recent funding?
AMBOSS secured €240M to enhance its platform and expand its offerings for healthcare professionals, significantly solidifying its market position.
Who are the new investors backing AMBOSS?
Investors such as KIRKBI, M&G Investments, and Lightrock have joined existing shareholders to support AMBOSS’s growth journey.
How does AMBOSS empower healthcare professionals?
AMBOSS provides trusted medical information and tools, enabling healthcare professionals to make informed clinical decisions efficiently.
What technologies are integrated into the AMBOSS platform?
AMBOSS combines the expertise of medical professionals with AI technology to deliver actionable insights and clinical recommendations.
How many users does AMBOSS have globally?
Over 1 million healthcare professionals across 180 countries utilize AMBOSS for education and clinical support.
